Latest
After a 48% One-Year Run, Investors Turn to Eli Lilly’s Next Set of Milestones
Eli Lilly’s stock has surged on expectations for its GLP-1 and obesity pipeline, but the company’s own updates highlight how quickly policy, pricing, and uptake can change the outlook.
The Apex Times / Jun 7, 6:27 AM EDT / 1 min read
Read the brief